Intellia has provided early, proof of principle, data that suggest CRISPR-based therapies can be given more than once to achieve stronger effects.
Three people with the inherited disease transthyretin amyloidosis produced significantly less of the misshapen protein causing their disease after receiving a second, stronger dose of a CRISPR-based medicine.
Biopharma Dive has more information.
